Quick Test Lab Diagnostics LLC — Billing Profile & Reimbursement Data

QUICK TEST LAB DIAGNOSTICS LLC operates as a high-throughput molecular clinical laboratory focused on amplified nucleic acid probe techniques; its top Medicare procedure 87798 and multiple other high-volume CPTs (87481, 87529, 87591, 87653, 87640, 87651, 87641, 87491) are all descriptions of nucleic-acid amplification tests for infectious agents and STIs, indicating an operational emphasis on infectious disease and sexually transmitted infection diagnostics rather than broad clinical chemistry or anatomic pathology services. The presence of multiplex respiratory codes (e.g., 87631) and genetic tests (81249, 81226) in the Medicare mix shows some diversification into respiratory panels and targeted molecular/genetic testing, but the core business is clearly molecular infectious disease testing.

Medicare revenue is heavily concentrated in a small set of molecular tests: the provider’s top three Medicare codes account for 63.6% of its total Medicare revenue, with 87798 alone contributing $1.6M (44.1% of Medicare revenue). That concentration signals reliance on a few high-volume assays for the majority of the Medicare topline.

Medicaid revenue is even more concentrated: the top three Medicaid codes account for 74.2% of the provider’s total Medicaid revenue, and 87798 dominates that payer as well with $129.6K (52.2% of Medicaid revenue). This concentration in a single amplified-probe category for Medicaid suggests limited diversification in the state payer mix and dependence on high-volume infectious-agent testing.

The provider is effectively Medicare-dominant on scale: lifetime Medicare revenue of $3.8M dwarfs lifetime Medicaid revenue of $248.5K, indicating that Medicare is the primary commercial outlet for its testing volume. That payer mix implies the organization’s operational and reimbursement exposure is heavily weighted toward Medicare contracting and payment policies.

National competitive standing on Medicare shows that QUICK TEST LAB DIAGNOSTICS is a high-volume participant for several specific molecular tests: 87481 ranks #27 of 1117 providers (98th percentile) and 87529 ranks #7 of 290 providers (98th percentile), both described as "notably above typical national volume." At the same time 87798 ranks #39 of 1319 providers (97th percentile) and is labeled "typical, unremarkable volume," so the provider is a clear national leader on select STI and related assays while being a more typical participant on broader unspecified-agent amplified tests.

In-state competitive standing for Medicaid is mixed but shows leadership on some tests: 87653 ranks #2 of 22 providers (95th percentile; "notably above typical state volume") and 87563 ranks #1 of 5 providers (100th percentile; "notably above typical state volume"), indicating the lab is a leading in-state provider for particular molecular assays. Other Medicaid codes such as 87798 rank #7 of 33 (81st percentile; "typical, unremarkable volume"), so the provider leads in select niches rather than across all test types statewide.

Reimbursement patterns differ by payer and test type: many amplified-probe Medicare tests show an average paid/claim of $34 (e.g., 87798, 87481, 87529 series), while certain multiplex or specialized assays carry higher per-claim payments—87631 shows $140 avg paid/claim on Medicare and 87633 shows $263 avg paid/claim on Medicaid. The contrast between a $34 baseline for many single-target amplified tests and substantially higher per-claim payments for multiplex panels or state Medicaid-negotiated rates suggests revenue sensitivity to test mix and payer-specific reimbursement structures.

The provider’s NPI was enumerated on 2021-01-26 (~5 years ago), indicating relatively recent entry into Medicare/Medicaid billing yet rapid scale-up: achieving $3.8M in Medicare revenue and notable national percentile rankings for multiple codes within roughly five years points to fast operational growth and strong uptake of its molecular testing services. This tenure and scale should be considered when evaluating contractual leverage and capacity for expanding test offerings.